Home › Companies › Vera Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Vera Therapeutics, Inc.’s Form 8-K, filed May 26, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 21, 2026: 5 items on Vera Therapeutics, Inc.’s Form 8-K, filed May 26, 2026: 3 elected · 2 approved.
Significant dissent: 1 director (23.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Vera Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Vera Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Michael M. Morrisey, Ph.D. | 45,288,710 | -- | -- | 13,814,671 | 2,863,469 | 77% | Elected | — |
| Elect Director: Patrick G. Enright | 54,697,296 | -- | -- | 4,406,085 | 2,863,469 | 93% | Elected | — |
| Elect Director: James R. Meyers | 58,946,269 | -- | -- | 157,112 | 2,863,469 | 99.7% | Elected | — |
| 2. Ratification of the Appointment of Independent Registered Public Accounting Firm | 61,834,842 | 44,710 | 87,298 | -- | -- | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 56,585,568 | 2,433,537 | 84,276 | -- | 2,863,469 | 96% | Approved | — |
Source: Vera Therapeutics, Inc., Form 8-K, filed with the SEC on May 26, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
232 asset managers disclosed a vote on at least one Vera Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: James R. Meyers
Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: James R. Meyers”): 58,946,269 for, 157,112 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 17,991,670 for, 25,399 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 3,286,052 | 0 | 0 | 0 | For |
| Vanguard | 3,197,621 | 0 | 0 | 0 | For |
| Fidelity | 2,919,238 | 0 | 0 | 0 | For |
| BlackRock | 2,564,567 | 0 | 0 | 0 | For |
| State Street | 2,031,076 | 0 | 0 | 0 | For |
| American Century | 540,540 | 0 | 0 | 0 | For |
| Charles Schwab | 524,826 | 0 | 0 | 0 | For |
| AllianceBernstein | 434,993 | 0 | 0 | 0 | For |
| TIAA | 424,493 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 265,992 | 0 | 0 | 0 | For |
| Equitable | 248,400 | 0 | 0 | 0 | For |
| Voya | 190,702 | 0 | 0 | 0 | For |
| Brighthouse | 110,246 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,792 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 97,375 | 0 | 0 | 0 | For |
| Principal | 96,696 | 0 | 0 | 0 | For |
| Dimensional | 90,833 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,412 | 0 | 0 | 0 | For |
| DWS | 59,554 | 0 | 0 | 0 | For |
| ProShares | 57,782 | 0 | 0 | 0 | For |
| Transamerica | 53,604 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 53,488 | 0 | 0 | 0 | For |
| Calamos | 46,974 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,908 | 0 | 0 | 0 | For |
| John Hancock | 43,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Michael M. Morrissey, Ph.D.
Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael M. Morrisey, Ph.D.”): 45,288,710 for, 13,814,671 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 13,706,862 for, 4,285,668 withheld, 24,539 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 3,286,052 | 0 | 0 | 0 | For |
| Vanguard | 3,195,159 | 0 | 23 | 2,439 | For |
| Fidelity | 2,919,238 | 0 | 0 | 0 | For |
| BlackRock | 2,564,567 | 0 | 0 | 0 | For |
| State Street | 4,540 | 0 | 0 | 2,026,536 | Withhold |
| American Century | 0 | 0 | 0 | 540,540 | Withhold |
| Charles Schwab | 524,826 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 434,993 | Withhold |
| TIAA | 424,493 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 265,992 | Withhold |
| Equitable | 107,025 | 0 | 0 | 141,375 | Mixed |
| Voya | 0 | 0 | 0 | 190,702 | Withhold |
| Brighthouse | 90,626 | 0 | 0 | 19,620 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 97,792 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 97,375 | Withhold |
| Principal | 0 | 0 | 0 | 96,696 | Withhold |
| Dimensional | 0 | 0 | 0 | 90,833 | Withhold |
| Goldman Sachs | 79,412 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 59,554 | Withhold |
| ProShares | 0 | 0 | 0 | 57,782 | Withhold |
| Transamerica | 53,604 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 53,488 | Withhold |
| Calamos | 46,974 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 43,908 | Withhold |
| John Hancock | 27,378 | 0 | 15,697 | 0 | Mixed |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Patrick G. Enright
Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Patrick G. Enright”): 54,697,296 for, 4,406,085 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 16,077,761 for, 1,939,301 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 3,286,052 | 0 | 0 | 0 | For |
| Vanguard | 2,646,262 | 0 | 7 | 551,352 | Mixed |
| Fidelity | 2,919,238 | 0 | 0 | 0 | For |
| BlackRock | 2,564,567 | 0 | 0 | 0 | For |
| State Street | 2,030,996 | 0 | 0 | 80 | For |
| American Century | 540,540 | 0 | 0 | 0 | For |
| Charles Schwab | 524,826 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 434,993 | Withhold |
| TIAA | 424,493 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 265,992 | Withhold |
| Equitable | 107,025 | 0 | 0 | 141,375 | Mixed |
| Voya | 0 | 0 | 0 | 190,702 | Withhold |
| Brighthouse | 110,246 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,792 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 97,375 | 0 | 0 | 0 | For |
| Principal | 5,051 | 0 | 0 | 91,645 | Mixed |
| Dimensional | 0 | 0 | 0 | 90,833 | Withhold |
| Goldman Sachs | 79,412 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 59,554 | Withhold |
| ProShares | 57,782 | 0 | 0 | 0 | For |
| Transamerica | 53,604 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 53,488 | 0 | 0 | 0 | For |
| Calamos | 46,974 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,908 | 0 | 0 | 0 | For |
| John Hancock | 43,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 96.6% for (May 14, 2025 meeting) ▼ 0.7 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.
Vera Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 56,585,568 for, 2,433,537 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 3,286,052 | 0 | 0 | 0 | For |
| Vanguard | 3,197,619 | 2 | 0 | 0 | For |
| Fidelity | 2,919,238 | 0 | 0 | 0 | For |
| BlackRock | 2,564,567 | 0 | 0 | 0 | For |
| State Street | 2,030,212 | 864 | 0 | 0 | For |
| American Century | 0 | 540,540 | 0 | 0 | Against |
| Charles Schwab | 524,826 | 0 | 0 | 0 | For |
| AllianceBernstein | 434,993 | 0 | 0 | 0 | For |
| TIAA | 424,493 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 265,992 | 0 | 0 | 0 | For |
| Equitable | 248,400 | 0 | 0 | 0 | For |
| Voya | 190,702 | 0 | 0 | 0 | For |
| Brighthouse | 110,246 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,792 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 97,375 | 0 | 0 | 0 | For |
| Principal | 96,696 | 0 | 0 | 0 | For |
| Dimensional | 90,833 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,412 | 0 | 0 | 0 | For |
| DWS | 59,554 | 0 | 0 | 0 | For |
| ProShares | 57,782 | 0 | 0 | 0 | For |
| Transamerica | 53,604 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 53,488 | 0 | 0 | 0 | For |
| Calamos | 46,974 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,908 | 0 | 0 | 0 | For |
| John Hancock | 43,075 | 0 | 0 | 0 | For |
Fund voting reports, all 66 managers: 17,403,903 for, 587,767 against, 25,399 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 4,993,061 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,578,714 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 0 | 3,337,893 | Withhold |
| State Street | 3,222,877 | 9,747 | 0 | 0 | For |
| Fidelity | 2,772,518 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 2,692,617 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,055,797 | 0 | 0 | 0 | For |
| BlackRock | 2,010,179 | 5,246 | 0 | 0 | For |
| Eversept Partners, LP | 1,728,485 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,563,271 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 1,440,942 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,257,400 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,079,213 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 957,936 | 0 | 0 | 0 | For |
| Point72 | 697,618 | 0 | 0 | 0 | For |
| American Century | 0 | 592,441 | 0 | 0 | Against |
| Integral Health Asset Management, LLC | 589,081 | 0 | 0 | 0 | For |
| Charles Schwab | 530,678 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 503,585 | 0 | 0 | 0 | For |
| Vanguard | 503,442 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 475,335 | 0 | 0 | Against |
| Woodline Partners LP | 469,708 | 0 | 0 | 0 | For |
| Northern Trust | 438,823 | 6,443 | 0 | 0 | For |
| Nuveen | 437,493 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 398,696 | 0 | 0 | 0 | For |
Institutional-manager reports, all 186 managers: 39,198,030 for, 1,768,203 against, 3,337,893 withheld, 258 abstained, 162 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (May 14, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Vera Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 61,834,842 for, 44,710 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 17,987,631 for, 80 against, 25,399 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 3,286,052 | 0 | 0 | 0 | For |
| Vanguard | 3,197,621 | 0 | 0 | 0 | For |
| Fidelity | 2,919,238 | 0 | 0 | 0 | For |
| BlackRock | 2,564,567 | 0 | 0 | 0 | For |
| State Street | 2,030,996 | 80 | 0 | 0 | For |
| American Century | 540,540 | 0 | 0 | 0 | For |
| Charles Schwab | 524,826 | 0 | 0 | 0 | For |
| AllianceBernstein | 434,993 | 0 | 0 | 0 | For |
| TIAA | 424,493 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 265,992 | 0 | 0 | 0 | For |
| Equitable | 248,400 | 0 | 0 | 0 | For |
| Voya | 190,702 | 0 | 0 | 0 | For |
| Brighthouse | 110,246 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,792 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 97,375 | 0 | 0 | 0 | For |
| Principal | 96,696 | 0 | 0 | 0 | For |
| Dimensional | 90,833 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,412 | 0 | 0 | 0 | For |
| DWS | 59,554 | 0 | 0 | 0 | For |
| ProShares | 57,782 | 0 | 0 | 0 | For |
| Transamerica | 53,604 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 53,488 | 0 | 0 | 0 | For |
| Calamos | 46,974 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,908 | 0 | 0 | 0 | For |
| John Hancock | 43,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,782,904 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 4.58% |
| 2 | Vanguard | 4.45% |
| 3 | Fidelity | 4.07% |
| 4 | BlackRock | 3.57% |
| 5 | State Street | 2.83% |
| 6 | American Century | 0.75% |
| 7 | Charles Schwab | 0.73% |
| 8 | AllianceBernstein | 0.61% |
| 9 | TIAA | 0.59% |
| 10 | AB DISCOVERY GROWTH FUND, INC. | 0.37% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Avoro Capital Advisors LLC | 6.96% |
| 2 | T. Rowe Price | 6.38% |
| 3 | Kynam Capital Management, LP | 4.65% |
| 4 | State Street | 4.50% |
| 5 | Fidelity | 3.86% |
| 6 | Deep Track Capital, LP | 3.75% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 2.86% |
| 8 | BlackRock | 2.81% |
| 9 | Eversept Partners, LP | 2.41% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.18% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 5,088,102 | 7.09% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 4,574,030 | 6.37% | Form 13F, quarter ended March 31, 2026 |
| Deep Track Capital, LP | 3,921,362 | 5.46% | Schedule 13G, filed March 11, 2026 |
| Vanguard Group | 3,570,401 | 4.97% | Form 13F, quarter ended March 31, 2026 |
| State Street | 3,363,638 | 4.69% | Form 13F, quarter ended March 31, 2026 |
| Sofinnova Venture Partners X, L.P. ("SVP X") | 2,793,987 | 3.89% | Schedule 13D, filed March 5, 2026 |
| FMR (Fidelity) | 2,676,422 | 3.73% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 1,570,077 | 2.19% | Form 13F, quarter ended March 31, 2026 |
| Point72 | 1,228,525 | 1.71% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 1,133,969 | 1.58% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 71,782,904 shares outstanding, as reported by Vera Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Vera Therapeutics, Inc.'s shareholder meeting held May 21, 2026, in the 2025-2026 proxy season, 232 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,361 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Vera Therapeutics, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Vera Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 26, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vera Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Vera Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Vera Therapeutics (VERA) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/vera-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.